Oxford BioDynamics PLC Director/PDMR Shareholding (0951R)

TIDMOBD

RNS Number : 0951R

Oxford BioDynamics PLC

01 July 2022

Oxford BioDynamics Plc

( " OBD " or the " Company " and, together with its subsidiaries, the " Group " )

PDMR Dealing

Oxford, UK - 1 July 2022 - Oxford BioDynamics Plc (AIM: OBD) announces that it has received notice that Dr Jon Burrows, the Group's Chief Executive Officer and an Executive Director, has purchased 65,000 Ordinary Shares of 1 pence each ("shares") at an average price of 13.48p per share.

Following this transaction, Dr Burrows is interested in 150,000 shares, representing 0.15% of the Company's current issued share capital.

The notification below, made in accordance with the requirements of UK Market Abuse Regulation, provides further details:

 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                             Jon Burrows 
     -------------------------------  -------------------------------------- 
 2    Reason for the notification 
     ----------------------------------------------------------------------- 
 a)   Position/status                  Director/PDMR 
     -------------------------------  -------------------------------------- 
 b)   Initial notification/            Initial notification 
       Amendment 
     -------------------------------  -------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------- 
 a)   Name                             Oxford BioDynamics Plc 
     -------------------------------  -------------------------------------- 
 b)   LEI                              2138005Y1TK258O5U928 
     -------------------------------  -------------------------------------- 
 4    Details of the transaction(s): section to be repeated for (i) 
       each type of instrument; (ii) each type of transaction; (iii) 
       each date; and (iv) each place where transactions have been 
       conducted 
     ----------------------------------------------------------------------- 
 a)   Description of the               Ordinary Shares of 1 pence each 
       financial instrument,            ISIN: GB00BD5H8572 
       type of instrument 
       Identification code 
     -------------------------------  -------------------------------------- 
 b)   Nature of the transaction        Acquisition of ordinary shares 
     -------------------------------  -------------------------------------- 
 c)   Price(s) and volume(s)             Price(s)   Volume(s) 
                                            0.1345      23,933 
                                                    ---------- 
                                             0.135      41,067 
                                                    ---------- 
     -------------------------------  -------------------------------------- 
 d)   Aggregated information             Price    Volume 
       - Aggregated volume                0.1348   65,000 
       - Price                                    ------- 
     -------------------------------  -------------------------------------- 
 e)   Dates of the transactions        30 June 2022 
     -------------------------------  -------------------------------------- 
 f)   Place of the transaction         London Stock Exchange (XLON) 
     -------------------------------  -------------------------------------- 
 

For further details please contact:

 
 Oxford BioDynamics Plc 
  Jon Burrows, CEO 
  Paul Stockdale, CFO                                 [phone] 
 Shore Capital 
  Nominated Adviser and Broker 
  Stephane Auton 
  John More                                          [phone] 
 Instinctif Partners                            Tel: [phone] 
 Melanie Toyne-Sewell / Jonjo Cordey    [e-mail] 
 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch(R) CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch (R) CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch(R) Explorer Array Kit .

The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch(R), which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial office in Gaithersburg, MD, USA and a reference laboratory in Penang, Malaysia.

For more information, please visit the Company's website, www.oxfordbiodynamics.com , or follow on Twitter or LinkedIn .

About EpiSwitch(R)

The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch(R) can be used to diagnose patients or determine how individuals might respond to a disease or treatment.

Built on over 10 years of research, EpiSwitch(R) is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.

In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch(R) data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFLEDFILIIF

(END) Dow Jones Newswires

July 01, 2022 11:13 ET (15:13 GMT)